Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ironwood Pharma (IRWD) to Resume Trading at 8:30 am ET
May 1, 2018 8:20 AM EDTIronwood Pharma (NASDAQ: IRWD) to Resume Trading at 8:30 am ET
... MoreIronwood Pharma (IRWD) to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business
May 1, 2018 8:00 AM EDTIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that its Board of Directors has authorized an intent to separate into two independent, publicly traded companies (Ironwood and R&D Co.). The separation is expected to be completed in the first half of 2019 and is anticipated to be tax-free to Ironwood shareholders.
... More
Ironwood Pharma (IRWD) Misses Q1 EPS by 4c
May 1, 2018 7:56 AM EDTIronwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.27), $0.04 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $69.16 million versus the consensus estimate of $78.87 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More